View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcar...

Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Wednesday, January 14, 2026. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of San...

 PRESS RELEASE

Sana Biotechnology Announces Publication in Nature Biotechnology of in...

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology  Broadens Application of Fusogen Technology Beyond T Cells to Second Cell Type, HSCs, Showing Potent and Specific in vivo Delivery Underscores Ability of Fusogen Technology to Deliver Diverse Payloads, including CRISPR Gene-Editing and Base-Editin...

 PRESS RELEASE

Sana Biotechnology to Present at December 2025 Investor Conferences

Sana Biotechnology to Present at December 2025 Investor Conferences SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. Sana will present at Citi’s 2025 Global Healthcare Conference at 2:30 p.m. ET on Tuesday, December 2, 2025.Sana will present at the 8th Annua...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Sana Biotechnology Reports Third Quarter 2025 Financial Results and Bu...

Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates Announced increased focus on type 1 diabetes and in vivo CAR T programs Regulatory interactions increase confidence in moving forward with GMP master cell bank for SC451, nonclinical testing plan, and path to filing SC451 Investigational New Drug Application (IND) as early as 2026 The New England Journal of Medicine published positive 12-week clinical results of ongoing type 1 diabetes study with UP421,which demonstrate that Sana’s hypoimmune-modified pancreatic islet cells are safe and well-tolerated, su...

 PRESS RELEASE

Sana Biotechnology to Present at the TD Cowen Immunology & Inflammatio...

Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit SEATTLE, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the TD Cowen Immunology & Inflammation Summit at 1:30 p.m. ET on Wednesday, November 12, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana’s web...

David Nierengarten ... (+6)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Sana Biotechnology to Present at September 2025 Investor Conferences

Sana Biotechnology to Present at September 2025 Investor Conferences SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update. Sana will present at Citi’s 2025 Biopharma Back-to-School Conference at 3:15 p.m. ET on Tuesday, September 2, 2025.Sana will present at the 2025 Wells Fargo Healthcare Conference at 8:00 a.m. ET on ...

 PRESS RELEASE

Sana Biotechnology Announces Closing of Full Exercise of Underwriters’...

Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has closed the sale of 3,358,208 shares of its common stock at a price to the public of $3.35 per share, pursuant to the exercise in full of the underwriters’ option to purchase additional shares in connection with Sana’s previously announced underwritten public offering, which closed on...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch